{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"The corneal events were graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results are presented for number of participants with any corneal events by maximum grade as per CTCAE grade version (v) 5.0.","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG002","title":"2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab"}],"populationDescription":"No participants were enrolled as CE Phase was not initiated due to business strategic reason.","reportingStatus":"POSTED","timeFrame":"Up to approximately 281 weeks.","title":"CE Phase: Number of Participants With Any Corneal Events by Maximum Grade as Per CTCAE Grade","type":"SECONDARY"}